Table 2—

Phase 1: outcome data^#

	Suspected PE patients
	Total	Suitable for early discharge	Unsuitable for early discharge
End of acute LMWH treatment
Subjects n	225	98	127
Thromboembolic event	0 (0; 0.0–1.6)	0 (0; 0.0–3.7)	0 (0; 0.0–2.9)
Bleeding complications
Minor bleed	1 (0.4; 0.0–2.5)	0 (0; 0.0–3.7)	1 (0.8; 0.0–4.3)
Major bleed	0 (0; 0.0–1.6)	0 (0; 0.0–3.7)	0 (0; 0.0–2.9)
Deaths	0 (0; 0.0–1.6)	0 (0; 0.0–3.7)	0 (0; 0.0–2.9)
3 months after start of PE treatment
Subjects n	202	85	117
Thromboembolic event	6 (3.0; 1.1–6.4)	2 (2.4; 0.3–8.2)	4 (3.4; 0.9–8.5)
Bleeding complications
Minor bleed	4 (2.0; 0.5–5.0)	3 (3.5; 0.7–10.0)	1 (0.9; 0.0–4.7)
Major bleed	6 (3.0; 1.1–6.4)	3 (3.5; 0.7–10.0)	3 (2.6; 0.5–7.3)
Deaths	9 (4.5; 2.1–8.3)	3 (3.5; 0.7–10.0)	6 (5.1; 1.9–10.8)

Data are presented as n (%; 95% confidence interval), unless otherwise stated. PE: pulmonary embolism; LMWH: low molecular weight heparin.^#: n = 225, 3-month follow-up data available for 202.